Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.35 |
| ▸ | HTR2A | P28223 | 10/20 | 0.35 |
| ▸ | HTR2B | P41595 | 7/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436034 | 0.85 | HTR2C (0.41) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL705701 | 0.85 | HTR2C (0.41) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL1480259 | 0.77 | FUT7 (0.39) | — | |
| SCHEMBL229770 | 0.77 | HTR2A (0.33) | HTR2CHTR2AHTR2BMTNR1A | |
| SCHEMBL436395 | 0.75 | HTR2C (0.38) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL251263 | 0.75 | HTR2C (0.38) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL9720820 | 0.71 | HTR2C (0.35) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL8937976 | 0.70 | LMNA (0.36) | — | |
| SCHEMBL1845859 | 0.70 | LMNA (0.36) | — | |
| SCHEMBL20562552 | 0.69 | HTR2C (0.51) | HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778910-B2 | Concentrated lamellar liquid personal cleansing composition | CONOPCO, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20140162979-A1 | CONCENTRATED LAMELLAR LIQUID PERSONAL CLEANSING COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2014-06-12 | — | — | US | claimed |
| US-7399731-B2 | Electrically conductive non-aqueous wellbore fluid | M-I L.L.C. (US) | 2008-07-15 | — | — | US | claimed |
| EP-1608392-A4 | PAPANICOLAU STAINING PROCESS | CYTYC CORP (US) | 2007-09-05 | — | — | EP | claimed |
| US-7186522-B2 | Using detergents to reduce artifacts during staining of biological samples; medical diagnostics and cervical cancer | CYTYC CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-20070003998-A1 | Papanicolau staining process | THIRD WAVE TECHNOLOGIES, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1608392-A2 | PAPANICOLAU STAINING PROCESS | Cytyc Corporation (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2004086945-A2 | PAPANICOLAU STAINING PROCESS | CYTYC CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-20220204968-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| US-20220002708-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| US-10914657-B2 | Fixative and staining solutions | ROCHE DIAGNOSTICS HEMATOLOGY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10656056-B2 | Fixative and staining solutions | ROCHE DIAGNOSTICS HEMATOLOGY, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180113059-A1 | FIXATIVE AND STAINING SOLUTIONS | CONSTITUTION MEDICAL, INC. | 2018-04-26 | — | — | US | disclosed |
| US-20040191854-A1 | Papanicolau staining process | CYTYC CORPORATION | 2004-09-30 | — | — | US | disclosed |
| WO-2004033574-A1 | CMP METHOD UTILIZING AMPHIPHILIC NON-IONIC SURFACTANTS | CABOT MICROELECTRONICS CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003104343-A2 | METHOD FOR CHEMICAL MECHANICAL POLISHING (CMP) OF LOW-K DIELECTRIC MATERIALS | CABOT MICROELECTRONICS CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030228762-A1 | CMP compositions for low-k dielectric materials | CABOT MICROELECTRONICS CORPORATION | 2003-12-11 | — | — | US | disclosed |
| US-20030228763-A1 | CMP method utilizing amphiphilic nonionic surfactants | CABOT MICROELECTRONICS CORPORATION | 2003-12-11 | — | — | US | disclosed |
| US-20030132033-A1 | Electrically conductive non-aqueous wellbore fluid | M-I L.L.C. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162979-A1 | CONCENTRATED LAMELLAR LIQUID PERSONAL CLEANSING COMPOSITION | SMURF1, SMURF2, ABHD16A | HTR2C 3447/4885HTR2A 2436/4885HTR2B 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.